158 related articles for article (PubMed ID: 30106102)
21. shRNA‑mediated silencing of TARBP2 inhibits NCI‑H1299 non‑small cell lung cancer cell invasion and migration via the JNK/STAT3/AKT pathway.
Shi Y; Zuo D; Wang X; Han M; Wu Y
Mol Med Rep; 2016 Oct; 14(4):3725-30. PubMed ID: 27599909
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer.
Ge G; Wang A; Yang J; Chen Y; Yang J; Li Y; Xue Y
J Exp Clin Cancer Res; 2016 Jan; 35():13. PubMed ID: 26791086
[TBL] [Abstract][Full Text] [Related]
23. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
24. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-27b reverses docetaxel resistance of non-small cell lung carcinoma cells via targeting epithelial growth factor receptor.
Chen S; Wang Q; Zhou XM; Zhu JP; Li T; Huang M
Mol Med Rep; 2016 Jul; 14(1):949-54. PubMed ID: 27221512
[TBL] [Abstract][Full Text] [Related]
26. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
28. Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Li N; Li H; Su F; Li J; Ma X; Gong P
Int J Clin Exp Pathol; 2015; 8(8):9010-20. PubMed ID: 26464643
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
[TBL] [Abstract][Full Text] [Related]
30. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Zhao M; Gao FH; Wang JY; Liu F; Yuan HH; Zhang WY; Jiang B
Lung Cancer; 2011 Sep; 73(3):366-74. PubMed ID: 21333372
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of LINC00346 inhibits proliferation of non-small cell lung cancer cells through mediating JAK-STAT3 signaling pathway.
Wang F; Chen JG; Wang LL; Yan ZZ; Chen SP; Wang XG
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5135-5142. PubMed ID: 29228425
[TBL] [Abstract][Full Text] [Related]
32. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
33. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
35. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer.
Chen JJ; Yao PL; Yuan A; Hong TM; Shun CT; Kuo ML; Lee YC; Yang PC
Clin Cancer Res; 2003 Feb; 9(2):729-37. PubMed ID: 12576442
[TBL] [Abstract][Full Text] [Related]
36. Effect of TW37 on the growth of H1975 EGFR‑TKI‑resistant lung cancer cells and its underlying mechanisms.
Liu J; Yao X; Wu D; Ye Y; Wu Q; Liu S; Wu H
Mol Med Rep; 2018 Feb; 17(2):2509-2514. PubMed ID: 29207200
[TBL] [Abstract][Full Text] [Related]
37. Proliferating cell nuclear antigen promotes cell proliferation and tumorigenesis by up-regulating STAT3 in non-small cell lung cancer.
Wang L; Kong W; Liu B; Zhang X
Biomed Pharmacother; 2018 Aug; 104():595-602. PubMed ID: 29803172
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
